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sics of hormonal action and signal transduc-
tion, the book is divided into five sections
based on physiological systems. Each sec-
tion contains chapters devoted to specific
disorders affecting the system in question,
including (1) the hypothalamus, pituitary,
adrenal axis and thyroid; (2) the reproduc-
tive system; (3) the metabolic system; (4)
multi-system syndromes; and (5) bone and
calcium. For each disorder, a terse review of
normal physiology is followed by a detailed
delineation of epidemiology, pathophysiol-
ogy, clinical presentations, diagnostic tests,
and treatment strategies that are often pre-
sented in shaded boxes for quick reference. 
This clinically focused textbook is in-
tended for medical students and residents
who aspire to specialize in endocrinology. It
is also useful for generalists because many
of the conditions discussed are often first
evaluated in primary care offices. Addition-
ally, considering the changing demographics
with the ongoing obesity epidemic, Harri-
son’s Endocrinology is to be applauded for
allocating substantial space to obesity and
metabolic syndromes. Evaluation and man-
agement  algorithms  accompanying  every
category of disease will prove invaluable in
the clinical setting. Discussions of diagnostic
tests and medications include up-to-date in-
formation on efficacy trials and best practice
guidelines. In addition, the question set in the
appendix serves as practice for board exams.
One of the characteristics that sets this
book apart from other clinical manuals is its
emphasis  on  genetics.  This  emphasis  is
probably derived from editor Larry Jame-
son, who was a pioneer in identifying ge-
netic causes for endocrine disorders. Almost
every chapter contains a list of genes whose
mutations are implicated in pathogenesis. It
is a shame, however, that explanations of the
functions of many of the gene products are
limited to a minimum in the text. Clinicians
who want to dig beneath the surface would
greatly appreciate a little more elaboration
on the molecular mechanisms behind dis-
ease, perhaps including diagrams illustrat-
ing the relevant signaling pathways. Another
shortcoming  that  may  hinder  the  book’s
popularity with students is that the text in-
troduces a lot of medical jargon, especially
names  of  clinical  signs  and  maneuvers,
without definition or description. Conse-
quently, readers who are just beginning their
medical careers may find themselves con-
stantly looking up words as they read this
book.
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J. Markowtiz. New York: McGraw-Hill
Companies,  Inc.;  2011.  616  pp.  US
$70.00  Paperback.  ISBN:  978-
0071637954. 
Care at the Close of Life: Evidence and
Experience fills a much-needed niche by
providing guidance on how to care for pa-
tients  facing  progressive  or  terminal  ill-
nesses. Not only is it a wonderful source of
information for medical professionals, but it
also serves as an accessible resource for pa-
tients and their families to learn about a dif-
ficult topic: death and dying. Composed of
carefully selected articles published previ-
ously in the Journal of the American Med-
ical Association (JAMA), Care at the Close
of Life assembles the critical topics of pal-
liative care into a concise and poignant read. 
Each chapter of Care at the Close of Life
is structured around a patient case study,
which is further elaborated upon by the fam-
ily’s, patient’s, and physician’s perspectives.
These viewpoints are real-life examples and
are given to the reader in a conversational na-
ture, which illustrates the discussed topics in
an extremely meaningful and relevant man-
ner. Additionally, pertinent information about
diagnostic and treatment options is inter-
spersed  throughout  the  chapter,  which  is
summarized at the end of the chapter and fol-
lowed by a self-assessment quiz.
Care  at  the  Close  of  Life is  an  ex-
tremely comprehensive book that covers aBook reviews 499
broad series of topics ranging from com-
munication issues with patients to helping
physicians deal with psychological and eth-
ical issues. Although it is aimed at health
care providers who care for patients facing
serious illnesses, it is a relevant resource for
anyone who wants to learn more about pal-
liative care. Overall, Care at the Close of
Life is a very informative and a must-read
for those who are caring for patients with
life-limiting illnesses. Not only does it give
health care providers an understanding of
what needs to be addressed clinically, but
perhaps  more  importantly,  it  allows  for
providers to give insight into the experi-
ence, intuition, and compassion necessary
to care for patients — qualities that often
take years to develop. 
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Both biotechnology and pharmaceuti-
cal companies work to generate products
that will improve the quality of human life.
In recent years, the development of thera-
peutics has evolved considerably. Transla-
tional  Medicine  and  Drug  Discovery
explains the advances in drug development
and  discusses  the  flaws  in  the  current
methodology as well as how those flaws
might be addressed.
The book begins with a brief discus-
sion of the history of translational medi-
cine  and  notes  that  the  concept  has
prompted the formation of teams within
pharmaceutical  companies  that  follow
drugs  from  early  development  through
human trials. Subsequent chapters describe
pharmaceutical advances in diabetes, ath-
erosclerosis, obesity, bone disorders, neu-
roscience,  and  cancer.  Although  topics
such as drug targets, modeling systems,
and imaging techniques are discussed, the
primary focus of the book is the develop-
ment  and  use  of  biomarkers. The  work
concludes with an overview of coalitions
recently  formed  to  improve  health  care
such as the Innovative Medicines Initia-
tive, the Critical Path Institute, and the
Biomarkers Consortium.  
Many of the authors and the editors of
Translational Medicine and Drug Discov-
ery come from a pharmaceutical or biotech-
nological  background,  which  somewhat
narrows the scope of the book; very little
of the material is derived from academic or
government  institutions.  These  authors
offer valuable insight into industry, yet they
also repeatedly touch on an interesting con-
cept: the need to generate profits. Thera-
peutics and biomarkers are discussed in
terms of risks and profits, and special at-
tention is paid to minimizing failed invest-
ments. Interestingly, the book also offers
several examples of how economic con-
cerns  have  led  to  suboptimal  research,
which has in turn impaired the evaluation
of novel therapeutics. Such examples un-
derline the difficulty of improving patient
care while addressing necessary monetary
concerns. Although there are no obvious
solutions, the final chapter of the book dis-
cusses several possible ways of balancing
economics and therapeutics, such as facili-
tating company collaborations and gener-
ating new testing paradigms that will weed
out false leads at an early stage of develop-
ment.  
While it is not an overly technical or
exhaustive work, Translational Medicine
and Drug Discovery is certainly not for the
casual reader. It does, however, act as a
useful overview of the principles behind
industrial  therapeutic  development  and
will be of use to those with a scientific or
medical background. Further, those who
are interested in learning about the histor-
ical and ongoing development of biomark-
ers will certainly benefit from reading this
book.  
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